New novavax JN.1 vaccine trial aims to protect adults 50-64 from COVID
⭐️ VACCINE ⭐️
Ongoing
This study tests a single dose of an updated Novavax COVID-19 vaccine designed to target the JN.1 variant. About 6,500 healthy adults aged 50 to under 65 who are not at high risk for severe COVID will receive either the vaccine or a placebo. Researchers will track how well the va…
Phase: PHASE4 • Sponsor: Novavax • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:30 UTC